The difference between tremelimumab and tremelimumab

Tremelimumab (tremelimumab) is another name for tremelimumab, which is used in combination with durvalumab to treat hepatocellular carcinoma(act lA type of liver cancer that cannot be treated with surgery), used in combination with durvalumab and platinum-based chemotherapy to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Temsitumumab belongs to a class of drugs called monoclonal antibodies. It works by helping your immune system slow or stop the growth of cancer cells.

Temtumumab binds to CTLA-4 molecules on T cells, blocking the interaction between CTLA-4 and CD80/CD86, and allowing CD28 molecules on T cells to continue interacting with CD80/CD86 to fully activate T cells, which is needed to attack cancer. Once T cells are fully activated, they multiply, forming a powerful army of T cells that can hunt down cancer cells throughout the body and kill them wherever they are found. There may be other ways in which temsitumumab can help eliminate cancer, which are currently being studied.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.